MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Regional Innovation Clusters (RICs), Incubators, Accelerators, Technology Transfer, SBIR/STTR, OTA, Non-Traditionals & Triple Helix
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA)*
Organization & Developments: Kiniksa Pharmaceuticals
Parents
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA)*
Children
2019: Kiniksa Pharmaceuticals: Interesting, But No Catalyst Ahead_seekingalpha.com
2020: Kiniksa Announces Pipeline Progress and Reiterates 2020
2021: FDA Approved, First-Ever Treatment for Recurrent Pericarditis
2021: Kiniksa: A Look At Mavrilimumab
2022: Kiniksa Pharmaceuticals, Ltd. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Kiniksa Pharmaceuticals: This Enterprising BioTech Should Be On Your Stock Watchlist_ seekingalpha.com
2023: Kiniksa's Diversified Pipeline Augments Arcalyst Potential (NASDAQ:KNSA)
2024: Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag_ seekingalpha.com
2024: Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
2024: Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
2025: Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast
2025: Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain
Jumps
Finance & Acquisitions: Kiniksa Pharmaceuticals
Key People: Kiniksa Pharmaceuticals